References of "Bury, Thierry"
     in
Bookmark and Share    
Peer Reviewed
See detailEffects of Acute Injection of Methylprednisolone in Man on Immunological and Non-Immunological Histamine Release from Leucocytes and Its Potentiation by Interleukin-3
Louis, Renaud ULg; Bury, Thierry ULg; Corhay, Jean-Louis ULg et al

in Clinical & Experimental Allergy : Journal of the British Society for Allergy & Clinical Immunology (1994), 24(1), 60-5

We investigated the effects of intravenous injection of methylprednisolone (MPR) compared with placebo (saline) on ex vivo leucocytic histamine release in eight healthy volunteers. All subjects received ... [more ▼]

We investigated the effects of intravenous injection of methylprednisolone (MPR) compared with placebo (saline) on ex vivo leucocytic histamine release in eight healthy volunteers. All subjects received in a randomized and a single-blind manner the placebo and MPR, 20 mg and 125 mg, each injection given in 2 week intervals. On each occasion blood samples were taken just before and 24 h after the intravenous injection to determine circulating leucocyte counts and leucocytic histamine release induced by anti-IgE (1/2000) and FMP (Formyl-Methionyl-Phenylalanine) (10(-5) M) and its modulation by IL-3 (2 ng/ml). MPR 20 mg and 125 mg significantly increased circulating leucocyte counts (P < 0.05 and P < 0.001 respectively) but decreased leucocytic histamine content (P < 0.05 and P < 0.001 respectively) by 24 h. Placebo had no effect. As for circulating basophils, after 24 h they were decreased by 125 mg MPR (P < 0.05) but increased by 20 mg (P < 0.05). Anti-IgE-induced HR was significantly inhibited by 125 mg MPR (P < 0.05) but not by 20 mg MPR or by the placebo. In contrast, neither MPR (20 mg and 125 mg) nor placebo significantly reduced FMP-induced HR. The strong potentiation by IL-3 of HR evoked by anti-IgE and FMP at baseline (P < 0.001) persisted 24 h after injection of MPR or placebo (P < 0.001 except P < 0.05 for anti-IgE-induced HR after 125 mg MPR).(ABSTRACT TRUNCATED AT 250 WORDS) [less ▲]

Detailed reference viewed: 16 (3 ULg)
Peer Reviewed
See detailPlasma Histamine and Bronchial Reactivity in Allergic Asthma
Corhay, Jean-Louis ULg; Bury, Thierry ULg; Louis, Renaud ULg et al

in Allergy (1993), 48(7), 547-9

Histamine is an important mediator of allergic inflammation and bronchial hyperresponsiveness (BHR), a hallmark of asthma. Studies on the relationship between plasma histamine and BHR in allergic ... [more ▼]

Histamine is an important mediator of allergic inflammation and bronchial hyperresponsiveness (BHR), a hallmark of asthma. Studies on the relationship between plasma histamine and BHR in allergic asthmatic patients have yielded controversial results. We therefore measured plasma histamine and bronchial reactivity in 30 nonsmoker volunteers taking no medication. Eleven were normal subjects; 19 were stable, mildly allergic asthmatic patients. Venous blood was taken to measure blood cells and basal plasma histamine by radioimmunoassay. After blood sampling, all subjects underwent a measurement of PC20M (concentration of methacholine causing a 20% fall in FEV1). Mean plasma histamine levels were 0.21 +/- 0.1 ng/ml and 0.44 +/- 0.3 ng/ml in normal and asthmatic subjects, respectively (P < 0.05). We found a significant increase of blood eosinophils and basophils in asthmatic patients, and a positive correlation between plasma histamine and circulating basophils. PC20M was greater than 16 mg in normal volunteers, and mean PC20M was 2.1 +/- 2 mg/ml in asthmatic patients. PC20M did not correlate with plasma histamine levels, but it did so negatively with blood eosinophils. The increased plasma histamine concentration in mildly atopic asthmatic patients might be a consequence of the high basophil releasability of atopics and the higher basophil counts in allergic asthma. Plasma histamine is thus unlikely to be a determinant of BHR in asthma. [less ▲]

Detailed reference viewed: 17 (2 ULg)
Peer Reviewed
See detailErgospirométrie et pratique pneumologique
Bury, Thierry ULg; Corhay, Jean-Louis ULg; Louis, Renaud ULg et al

in Revue Médicale de Liège (1993), 48(9), 523-6

Detailed reference viewed: 115 (12 ULg)
Full Text
Peer Reviewed
See detailNo Increase in Plasma Histamine During Paf-Induced Airway Obstruction in Allergic Asthmatics
Louis, Renaud ULg; Bury, Thierry ULg; Corhay, Jean-Louis ULg et al

in CHEST (1993), 104(3), 806-10

To investigate the possible role of mast cell or basophil histamine release in mediating platelet-activating factor (PAF) airway obstruction, we studied the effect of inhaled PAF (30 micrograms, single ... [more ▼]

To investigate the possible role of mast cell or basophil histamine release in mediating platelet-activating factor (PAF) airway obstruction, we studied the effect of inhaled PAF (30 micrograms, single dose) on plasma histamine, bronchial caliber, and leukocyte and platelet counts in six patients with mild or moderate allergic asthma (mean age, 27 +/- 1.3 years; mean FEV1, 95 +/- 5 percent of predicted; mean PC20 methacholine, 1.46 +/- 0.36 mg/ml). Specific conductance (SGaw) FEV1, FEF25-75 percent, differential leukocyte and platelet counts, and plasma histamine (radioimmunoassay) were measured before and 5, 10, 15, and 20 min after PAF inhalation. Mean basal plasma histamine level was 0.28 +/- 0.04 ng/ml. Inhalation of PAF caused a fall in SGaw peaking at 5 min (43 +/- 9 percent) and a fall in FEV1 and FEF25-75 peaking at 10 min (19 +/- 10 percent and 30 +/- 13 percent, respectively). There was also a rapid and transient fall in circulating neutrophils at 5 min (from 3,096 +/- 204/mm3 to 2,551 +/- 158/mm3, p < 0.05) followed by a rebound neutrophilia. In contrast, plasma histamine level did not change significantly at any time measured. Conversely in the same asthmatics, a rapid rise in plasma histamine level (from 0.29 +/- 0.03 ng/ml at baseline to 0.53 +/- 0.06 ng/ml at 5 min; p < 0.01) was observed after an allergenic challenge (Dermatophagoides pteronyssinus) causing a fall in FEV1 peaking at 10 min (22 +/- 4 percent). Thus, inhaled PAF may induce airway obstruction and neutropenia in asthmatics without any significant change of plasma histamine level. These results indicate that it is unlikely that lung mast cells or basophils degranulate during PAF-induced bronchoconstriction. [less ▲]

Detailed reference viewed: 7 (1 ULg)
Peer Reviewed
See detailL'hyperréactivité bronchique non spécifique: données épidémiologiques et signification clinique
Louis, Renaud ULg; Corhay, Jean-Louis ULg; Bury, Thierry ULg et al

in Revue Médicale de Liège (1993), 48(4), 213-9

Detailed reference viewed: 92 (2 ULg)
Peer Reviewed
See detailChylothorax: a rare complication of endoscopic variceal sclerotherapy.
Bury, Thierry ULg; Corhay, Jean-Louis ULg; Louis, Renaud ULg et al

in European Journal of Gastroenterology & Hepatology (1993), 5

Detailed reference viewed: 7 (2 ULg)
Peer Reviewed
See detailLes syndromes hémorragiques pulmonaires diffus: approches clinique et diagnostique
Bury, Thierry ULg; Corhay, Jean-Louis ULg; Kotolenko, S. et al

in Revue Médicale de Liège (1992), 47(11), 554-9

Detailed reference viewed: 9 (4 ULg)
Peer Reviewed
See detailLy 186655, a Phosphodiesterase Inhibitor, Inhibits Histamine Release from Human Basophils, Lung and Skin Fragments
Louis, Renaud ULg; Bury, Thierry ULg; Corhay, Jean-Louis ULg et al

in International Journal of Immunopharmacology (1992), 14(2), 191-4

LY 186655 (Tibenelast, Lilly) is a new phosphodiesterase inhibitor, not derived from the xanthine, possessing bronchodilating activity in animals. The aim of this work was to study the effect of LY 186655 ... [more ▼]

LY 186655 (Tibenelast, Lilly) is a new phosphodiesterase inhibitor, not derived from the xanthine, possessing bronchodilating activity in animals. The aim of this work was to study the effect of LY 186655 and theophylline on histamine release from human leukocytes, skin and lung fragments. Histamine was measured using a spectrofluorometric method. Both drugs (3 x 10(-5)-3 x 10(-3) M) exhibited a dose-dependent inhibition on anti-IgE (1/2000)-induced histamine release from human leukocytes. At 3 x 10(-3) M, theophylline was significantly more effective than LY 186655 (mean inhibition 94 and 42%, respectively). On lung fragments, theophylline and LY 186655 (3 x 10(-5)-3 x 10(-3) M) caused strong and comparable inhibitory effects on anti-IgE (1/500)-induced histamine release with a mean inhibition reaching maximally 65%. Histamine release induced by compound 48/80 (1 mg/ml) on sliced human foreskin was reduced with both drugs (3 x 10(-3) M) by about 37%. We conclude that LY 186655 inhibits in vitro immunological histamine release from human lung and cutaneous mast cells as well as basophils with a similar pattern of activity to theophylline. [less ▲]

Detailed reference viewed: 36 (15 ULg)
Peer Reviewed
See detailA propos de 2 cas de lymphangiomyomatose traités par agoniste de la LH-RH
RADERMECKER, Marc ULg; Corhay, Jean-Louis ULg; Broux, R. et al

in Revue Médicale de Liège (1991), 46(5), 286-93

Detailed reference viewed: 20 (0 ULg)